Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals

• Published in: Molecular psychiatry 2020-07, Vol.25 (7), p.1526-1536
• Main Authors: Greenberg, Tsafrir, Fournier, Jay C., Stiffler, Richelle, Chase, Henry W., Almeida, Jorge R., Aslam, Haris, Deckersbach, Thilo, Cooper, Crystal, Toups, Marisa S., Carmody, Tom, Kurian, Benji, Peltier, Scott, Adams, Phillip, McInnis, Melvin G., Oquendo, Maria A., Fava, Maurizio, Parsey, Ramin, McGrath, Patrick J., Weissman, Myrna, Trivedi, Madhukar, Phillips, Mary L.
• Format: Article
• Language: English
• Subjects: 59/36; 631/378; 692/53/2423; Adult; Antidepressants; Antidepressive Agents - therapeutic use; Behavioral Sciences; Biological Psychology; Care and treatment; Depression, Mental; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - physiopathology; Dopamine; Dopamine receptors; Expectancy; Female; Functional magnetic resonance imaging; Humans; Male; Medicine; Medicine & Public Health; Mental depression; Neostriatum; Neurosciences; Neurotransmitters; Pharmaceutical industry; Pharmacotherapy; Placebos; Psychiatry; Reinforcement; Reward; Serotonin; Sertraline; Sertraline - therapeutic use; Ventral Striatum - drug effects; Ventral Striatum - physiology
• ISSN: 1359-4184; 1476-5578
• DOI: 10.1038/s41380-019-0490-5

Medications to treat major depressive disorder (MDD) are not equally effective across patients. Given that neural response to rewards is altered in MDD and given that reward-related circuitry is modulated by dopamine and serotonin, we examined, for the first time, whether reward-related neural activity moderated response to sertraline, an antidepressant medication that targets these neurotransmitters. A total of 222 unmedicated adults with MDD randomized to receive sertraline ( n  = 110) or placebo ( n  = 112) in the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study completed demographic and clinical assessments, and pretreatment functional magnetic resonance imaging while performing a reward task. We tested whether an index of reward system function in the ventral striatum (VS), a key reward circuitry region, moderated differential response to sertraline versus placebo, assessed with the Hamilton Rating Scale for Depression (HSRD) over 8 weeks. We observed a significant moderation effect of the reward index, reflecting the temporal dynamics of VS activity, on week-8 depression levels (Fs ≥ 9.67, ps ≤ 0.002). Specifically, VS responses that were abnormal with respect to predictions from reinforcement learning theory were associated with lower week-8 depression symptoms in the sertraline versus placebo arms. Thus, a more abnormal pattern of pretreatment VS dynamic response to reward expectancy (expected outcome value) and prediction error (difference between expected and actual outcome), likely reflecting serotonergic and dopaminergic deficits, was associated with better response to sertraline than placebo. Pretreatment measures of reward-related VS activity may serve as objective neural markers to advance efforts to personalize interventions by guiding individual-level choice of antidepressant treatment.